Trial Profile
Phase I, open-label study to evaluate steady-state serum and pulmonary pharmacokinetics following intravenous administration of zanamivir in healthy adult subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Aug 2023
Price :
$35
*
At a glance
- Drugs Zanamivir (Primary)
- Indications Influenza virus infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jul 2007 New trial record.